Sisram Medical (1696.HK) and Fosun Industrial Enter into a Sublicense Agreement for the Commercialization of DaxibotulinumtoxinA (RT002) Injectable
Sisram Medical Group expects to record significant increases of more than 73% in its revenue and more than 190% in its profits for the First 6 Months of 2021, as compared to that for the corresponding period in 2020.
Sisram Medical Expands its Dental Business Line with Proposed Acquisition of Shanghai Foshion Medical System, a Leading Dental Equipment Sales & Marketing Platform in China
Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?